Media coverage about KemPharm (NASDAQ:KMPH) has been trending somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. KemPharm earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.5076297477125 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

KemPharm (NASDAQ KMPH) traded down 14.06% on Monday, hitting $2.75. 250,290 shares of the stock were exchanged. The stock’s market capitalization is $40.31 million. KemPharm has a one year low of $2.65 and a one year high of $5.50. The company has a 50 day moving average of $3.48 and a 200 day moving average of $3.92.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.19. On average, equities research analysts forecast that KemPharm will post ($2.77) earnings per share for the current fiscal year.

A number of research firms have issued reports on KMPH. Royal Bank Of Canada reiterated a “buy” rating and issued a $8.00 target price on shares of KemPharm in a research report on Monday, May 15th. Zacks Investment Research downgraded shares of KemPharm from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Oppenheimer Holdings, Inc. set a $13.00 target price on shares of KemPharm and gave the stock a “buy” rating in a research report on Wednesday, May 10th. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 1st. Finally, Roth Capital began coverage on shares of KemPharm in a research report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.10.

TRADEMARK VIOLATION WARNING: “KemPharm (NASDAQ:KMPH) Earning Somewhat Positive News Coverage, Study Finds” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

In other KemPharm news, CEO Travis C. Mickle acquired 8,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were acquired at an average price of $3.45 per share, with a total value of $27,600.00. Following the completion of the transaction, the chief executive officer now directly owns 1,629,612 shares in the company, valued at approximately $5,622,161.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders bought 10,775 shares of company stock worth $38,783. 22.80% of the stock is currently owned by insiders.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.